The acquisition of Life Molecular Imaging by Lantheus for $350 million is a strategic move to enhance its product offerings in the Alzheimer's disease radiodiagnostic market. The addition of Neuraceq®, a globally approved imaging agent, is likely to strengthen Lantheus' market position and drive growth. This acquisition is expected to have a positive impact on Lantheus' stock price in the short term due to the expansion of its product portfolio and market reach.